Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MLN-518

Known as: CT-53518, CT53518, MLN518 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
PURPOSE FMS-like tyrosine kinase-3 (FLT3) internal tandem duplication (FLT3-ITD) mutations are common in patients with acute… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Acquired resistance to selective FLT3 inhibitors is an emerging clinical problem in the treatment of FLT3-ITD+ acute myeloid… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approximately 30% of acute myeloid leukemia (AML… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
http://bloodjournal.hematologylibrary.org/content/114/14/2984.full.html Updated information and services can be found at: (884… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2005
2005
FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase that is constitutively activated in approximately 30% of acute… Expand
  • figure 2
  • figure 1
  • table 1
Is this relevant?
Highly Cited
2004
Highly Cited
2004
FLT3 is constitutively activated by internal tandem duplications (ITDs) in the juxtamembrane domain or by activation loop… Expand
Is this relevant?
2004
2004
MLN518 is a small molecule inhibitor of FLT3, PDGFR and c-Kit that is currently being evaluated as a therapy for AML. Previous… Expand
Is this relevant?
2002
2002
We have previously found that the 4-[4-(N-substituted carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazolines can function as potent… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Up to 30% of acute myelogenous leukemia (AML) patients harbor an activating internal tandem duplication (ITD) within the… Expand
Is this relevant?